Pharma: Trends an...
Follow
Find
22.1K views | +0 today
 
Rescooped by eMedToday from #eHealthPromotion, #web2salute
onto Pharma: Trends and Uses Of Mobile Apps and Digital Marketing
Scoop.it!

Physicians preparing to adopt digital pill technologies

Physicians preparing to adopt digital pill technologies | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it

Next year, some family physicians likely will be using ingestible digital pills to keep track of patient's health, the New York Times' "Bits" reports (Bilton, "Bits", New York Times, 6/23).

 

Such pills feature an embedded microchip to transmit patient data to health care providers.

 

Last month, FDA said that it is easing federal oversight of the pills.

FDA said it is amending the Federal Food, Drug and Cosmetic Act -- which gives the agency regulatory authority -- to categorize digital pill technology as a class 2 medical device. Traditionally, new devices are automatically labeled as class 3 devices, which is more restrictive than class 2.

 

In July 2012, FDA approved Proteus Digital Health's microchip, a silicon wafer that is embedded in an ingestible pill.

 

The device generates electricity when it makes contact with the stomach's digestive fluids and sends a signal to a patch on the patient's skin.

 

The disposable patch then can transmit information to a health care provider's mobile phone application, including data on:

Time the pill is taken;Heart rate;Body position; andTemperature

In addition to Proteus' digital pill technology, HQ -- a Florida company -- has developed a pill that has a built-in battery and sends real-time body temperature updates as it moves through a patient's body.

 

Meanwhile, Regina Dugan -- senior vice president for Motorola Mobility's advanced technology and projects group -- at a digital technology conference last month showed an example of a digital pill that can wirelessly communicate with a smartphone application ("Bits", New York Times, 6/23).


Via Andrew Spong, Giuseppe Fattori
eMedToday's insight:

Brilliant way to increase adherence on drugs

more...
eMedToday's curator insight, June 25, 2013 8:21 PM

This could be part of an e detailing program. WOW

Pharma: Trends and Uses Of Mobile Apps and Digital Marketing
Keep current on Pharma uses of mobile apps
Curated by eMedToday
Your new post is loading...
Your new post is loading...
Rescooped by eMedToday from Pharma & Medical Devices
Scoop.it!

FDA Oversight in the Internet Age

FDA Oversight in the Internet Age | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
An FDA rebuke of televised comments made by Aegerion’s CEO—which led the company to air a TV commercial correcting the statements—was prompted by complaints from a government drug reviewer, according to emails viewed by The Wall Street Journal.

Via Richard Meyer
more...
Pharma Guy's curator insight, December 22, 8:35 AM


This was clearly an effort by a CEO to boost his company's share price and his personal profits, which undoubtedly depend on the price of the shares.


The Wall Street Journal Article also reveals that Mr. Beer, who became Aegerion’s CEO in 2010, "oversaw the company’s initial public offering and regulatory approval of Juxtapid, its first marketed drug. The Cambridge, Mass.-based company has 268 employees. Last year, Aegerion’s stock nearly tripled from $26.44 to $69.53 after Juxtapid sales got off to a strong start. However, a number of regulatory and legal problems, combined with disappointing Juxtapid sales, have caused the company’s share price to tumble nearly 69% to $22.81 since the beginning of 2014.


"Aegerion twice cut its sales guidance this year after it said more patients than expected quit taking Juxtapid because of the drug’s side effects, which include diarrhea, nausea and the risk of liver damage. Sales have also been hurt by an investigation by Brazilian authorities into whether Aegerion employees violated the country’s anticorruption laws in connection with the prescribing of Juxtapid there, the second-largest market for the drug after the U.S. The company said it doesn’t believe Brazil’s anticorruption laws have been broken.


The drug maker disclosed in January it is the subject of a U.S. Justice Department investigation into its sales and marketing of Juxtapid. The company said it is cooperating with the continuing investigation, and that it intends to vigorously defend itself."


Find the FDA letter here.

Rescooped by eMedToday from Pharma Hub
Scoop.it!

Update: In 2015, interesting digital health collaborations on tap for pharma

Update: In 2015, interesting digital health collaborations on tap for pharma | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it

A report published earlier this year illustrated the number of apps pharmaceutical companies produces and the conditions for which they have developed them. The apps are frequently designed to improve health literacy and motivate patients to take their medication to improve adherence, especially around chronic conditions.


Via Philippe Marchal/Pharma Hub
more...
Alexandre Gultzgoff's curator insight, December 22, 3:24 AM

patient engagement not in Sanofi's culture? let's change it at our level...

Bettina Gifford's curator insight, December 22, 2:03 PM

Which pharma company is most digitally active? 

malek's comment, December 24, 7:38 PM
Digitally enabled healthcare is here, and most pharmaceutical companies aren’t ready. bit.ly/1B75t8O
Rescooped by eMedToday from 9- PHARMA MULTI-CHANNEL MARKETING by PHARMAGEEK
Scoop.it!

Medical Meetings Face #Pharma Sponsorship Crisis

Medical Meetings Face #Pharma Sponsorship Crisis | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it

The medical meetings industry could face 'drastic changes' if pharmaceutical companies clamp down on their sponsorship of doctors.

 

More stringent regulations in the future could see pharma firms further discouraged from sponsoring doctors and other healthcare professionals to attend conferences.

 

And Richard Evans, director of NexGen Healthcare Communications, has warned that the industry needs to be prepared to change.

 

"If pharma stops spending money on sending people to meetings, then those meetings will change drastically," he told the Healthcare Meetings Forum at Park Inn by Radisson.

 

"If pharma does decide not to support physicians to attend those congresses then they will slowly wither on the vine."

 

The two-day forum aimed to consider the challenges facing the industry as it is faced with an increasing focus on compliance and financial transparency.

 

One doctor who addressed the 100 delegates admitted that without support from pharmaceutical companies, lower- and middle-grade healthcare professionals would struggle to afford to attend congresses.

 

"It is not obvious where else the money can come from - it is not going to come from my training budget," he said.

 

A representative from a pharmaceutical company told the conference it would depend on the circumstances.

 

"The budgets aren't changing per se, but we are using them differently. As long as we have a commercial benefit of having an exhibition, we will have an exhibition," he said. "We will sponsor physicians where we can, but if we don't have any products to promote or we don't see any value, we will of course not be sponsoring."

 

In 2013 Sir Andrew Witty, GlaxoSmithKline's chief executive, announced the company would no longer pay doctors to attend medical conferences or give lectures promoting its drugs.


Via Pharma Guy, Philippe Marchal/Pharma Hub, Lionel Reichardt / le Pharmageek
more...
Pharma Guy's curator insight, December 17, 7:07 AM


The pharmaceutical industry supports CME through grants to accredited providers such as medical societies, medical schools and for-profit Medical Education Communications Companies (MECC's). It also helps finance CME through advertising and exhibiting at CME events. I include the latter in my analysis of total pharma support, which decreased slightly (0.6%) in 2013 compared to 2012 (dropping from $1,006,327,936 in 2012 to $999,791,328 in 2013). Advertising and exhibit income, however, increased from $331.6 million in 2012 to $339.8 million in 2013. For more, read Total CME Revenue is Up, But Pharma Support is Down (Again)

Rescooped by eMedToday from 9- PHARMA MULTI-CHANNEL MARKETING by PHARMAGEEK
Scoop.it!

Facebook and pharma in 2014

Facebook and pharma in 2014 | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
 

Many of these are successful in engaging their audience, considering that there are several likes and shares on each post, as well as some being commented on (especially if they are topical, like Ebola). More robust engagement comes in the form of competitions, such as BI's asthma photography contest. This gets people involved in creating content as well as raising awareness of a therapy area without being promotional and involving product names.


Figure 3. BI's photography competition serves as the cover image and connects an Instagram campaign to their Facebook page.
 

Going one step further, J&J not only asks general questions to the fans of the page, but is also involved in the follow-up discussions. Having personal responses from the company is of high value to the customers, and the dialogue helps build reputation. Note that the key to avoiding regulatory issues is to ask something that is not likely to lead to any mention of products or adverse events.


Figure 4. J&J gets involved in the conversation about Halloween.


Regulations within the industry mean that comments may be removed and most pharmaceutical firms on Facebook have disclaimers on their pages stating that this may be a result of referencing drugs or their effects. This is made most clear by having a different visible tab on the page labelled 'Community Guidelines' or 'Comment Missing?' as done on the pages of J&J, Pfizer, and Novartis. Having an easy-to-understand and friendly section on these terms helps alleviate any customer frustration.



Figure 5. The information page for consumers on the Pfizer page is clear and friendly about the company's comment policy.


The importance of engagement

This is just a small glimpse into how pharmaceutical companies are using Facebook in their messaging to the public. Although the medium may seem constraining, there is still room for creativity in providing compelling information while remaining compliant. The easiest way to promote participation and interaction with the company is through contests, quizzes, conversations about daily life, games and other activities that go beyond the 'like'.

As mentioned earlier, Facebook has allowed users to not only chat with their friends, but also with companies. However, the ultimate goal should be that these companies become friends through open dialogue with their consumers and transparency regarding their regulatory situation, in order to gain the trust and support of the people they serve.

About the author:

Stefan Marcus is research strategist with Creation Healthcare, the engagement strategy consultancy to the global healthcare industry with a special interest in the digital behaviours of health stakeholders.


Via Plus91, Lionel Reichardt / le Pharmageek
more...
Birgit Bauer's curator insight, December 17, 3:20 AM

Interesting Insights ... 

Rescooped by eMedToday from 9- PHARMA MULTI-CHANNEL MARKETING by PHARMAGEEK
Scoop.it!

Pharma Marketing Blog: Pharma C-Suite Social Media Dummies: Can They Be Trained?

Pharma Marketing Blog: Pharma C-Suite Social Media Dummies: Can They Be Trained? | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it

Via Lionel Reichardt / le Pharmageek
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

New Standards for Pharmaceutical Digital Marketing

New Standards for Pharmaceutical Digital Marketing | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
How will the new standards for pharmaceutical digital marketing change your marketing strategy in 2015?
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

115 Mind Blowing mHealth and Telehealth Statistics and Trends

115 Mind Blowing mHealth and Telehealth Statistics and Trends | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Healthcare Trends in America, Check out 115 mHealth Facts at referralMD.
more...
No comment yet.
Rescooped by eMedToday from Pharma & Medical Devices
Scoop.it!

Does drug pricing reflect innovation? The evidence suggests not - and other 2015 biotech trends

Does drug pricing reflect innovation? The evidence suggests not - and other 2015 biotech trends | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
A rich new Credit Suisse report, "Global Biotechnology - An Outlook for 2015," was flush with cool data about trends in the biotech industry. The analysis lists out 10 key themes for 2015 - with drug pricing being among the more interesting themes.

Via Richard Meyer
more...
No comment yet.
Rescooped by eMedToday from #eHealthPromotion, #web2salute
Scoop.it!

10 Digital Health Trends Over The Next 20 Years

10 Digital Health Trends Over The Next 20 Years | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Earlier this week I participated in the world’s first online digital health conference, Digital Health Pulse, organized by digital health consultancy, Enspektos. Speaking at the ...

Via Giuseppe Fattori
more...
No comment yet.
Rescooped by eMedToday from Pharma Hub
Scoop.it!

Pharma must 'get on-board with digital health' to be more patient-focused

Pharma must 'get on-board with digital health' to be more patient-focused | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it

One of the ways pharma, and the wider healthcare sector, can become more patient-focused is to more fully embrace the impact digital can make on healthcare management, according to BMI Healthcare.


Via Philippe Marchal/Pharma Hub
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

Trends in B2B Marketing for 2015

Trends in B2B Marketing for 2015 | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
We’re fast-approaching the end of 2014. You know what that means: trend watching posts galore! Here’s my view on how I think 2015 will shape up for B2B marketers.
more...
No comment yet.
Rescooped by eMedToday from Mobile Health: How Mobile Phones Support Health Care
Scoop.it!

Novartis’ mobile health strategy poised to move from tracking to virtual care

Novartis’ mobile health strategy poised to move from tracking to virtual care | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
While Novartis’ recent partnership with Google and its longtime relationship with Proteus have indicated that the pharma company has an interest in digital health, a page on the company’s website, added this summer, lays out its broad vision and explicit interest in mobile health specifically. The company even has a mobile health strategy lead, Michele Angelaccio, who holds the title of Associate Director US Mobile Health Strategy at Novartis Pharmaceuticals.

Via Beeyond, dbtmobile
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

5 Digital Marketing Metrics That Aren't Very Important

5 Digital Marketing Metrics That Aren't Very Important | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Here are five digital marketing metrics to chop, and which stats should populate their places.
more...
No comment yet.
Rescooped by eMedToday from Hospitals: Trends in Branding and Marketing
Scoop.it!

How marketers will win: Six marketing visionaries describe how in five years marketing will be transformed

How marketers will win: Six marketing visionaries describe how in five years marketing will be transformed | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Marketing is on the ascent. It has frequently led at big consumer products companies. Now its influence is growing everywhere: at B2B companies, professional services firms, companies dominated by engineering or logistics. You can see marketing's rise on business bestseller lists, on YouTube playlists, in the new brands that have broken away and differentiated themselves, and in the explosion of marketing start-ups (and what investors are paying for them). Marketing is becoming a more powerful a

Via Lionel Reichardt / le Pharmageek, eMedToday
more...
No comment yet.
Rescooped by eMedToday from 9- PHARMA MULTI-CHANNEL MARKETING by PHARMAGEEK
Scoop.it!

Update: In 2015, interesting digital health collaborations on tap for pharma

Qualcomm LIfe General Manager Rick Valencia said we'll see a lot more collaboration between pharma companies next year as integrate digital health solutions.


Via dbtmobile, Lionel Reichardt / le Pharmageek
more...
No comment yet.
Rescooped by eMedToday from Health, Digital Health, mHealth, Digital Pharma, hcsm latest trends and news (in English)
Scoop.it!

Pharma companies want to add an app to your next prescription

Pharma companies want to add an app to your next prescription | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Pharmaceutical companies reported to be establishing a digital health collaborative; may add apps to your next prescription.

Via Celine Sportisse
more...
No comment yet.
Rescooped by eMedToday from Mobile Health: How Mobile Phones Support Health Care
Scoop.it!

10 Ideas That Are About To Revolutionize Medicine

10 Ideas That Are About To Revolutionize Medicine | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it


More More: Health Medicine Innovation Future
10 Ideas That Are About To Revolutionize Medicine

    Erin Brodwin

    Nov. 5, 2014, 6:00 AM
    1,070
    1    

    facebook
    linkedin
    twitter
    google+
    print
    email

elizabeth holmes theranosCourtesy Theranos

The future of medicine has arrived.

No, we're not talking about robot surgeons, implantable memory-augmentation devices, or doctors wearing Google Glass. The game-changing innovations on this list are more than distant dreams or inventions no one really knows what to with yet. Most should be available as early as 2015.

Every year, the Cleveland Clinic comes up with a list of new devices or treatments that are expected to help improve our daily lives and reduce our risks of developing disease. Only time will tell whether their considerable promise pans out.

Here are the top 10 new medications, treatments, and technologies to watch for in 2015, according to the Cleveland Clinic.
1. Mobile Stroke Unit

What if there were a drug that could lessen the brain damage caused by a stroke by targeting the blood clot that caused it and breaking it up?

As it turns out, there is. It's called tPA, and the faster it's given after a stroke, the safer and more effective it is. Here's the problem: Most people don't get the drug in time, and it can only be administered via IV. Lack of access to quick treatment can have dire consequences — someone in the US dies from stroke every four minutes.

Mobile stroke treatment units solve this problem by taking tPA directly to the patient. The units are essentially ambulances outfitted with everything health professionals need to treat a patient suffering from a stroke and staffed by an onboard paramedic, a critical care nurse, and a CT technologist. A broadband video link allows the onboard team to virtually contact a hospital stroke neurologist to guide treatment.
2. Dengue Vaccinepolio vaccine afghanistan childMohammad Ismail/Reuters

Close to half the world's population is at risk for developing dengue, a disease characterized by high fever, nausea and vomiting, and pain behind the eyes and in the muscles, bones, and joints. The virus kills some 20,000 people each year and is spread by mosquitoes. One of the biggest challenges in creating a vaccine against dengue is that it is caused by five different related, but not identical, strains. Even protection from one type will still leave you susceptible to the four other forms.

But scientists have reason to be hopeful this year.

A vaccine that just went through the last phase of testing was found to be 60% effective, on average, in protecting people against the disease, and 95.5% protective against the disease in its most severe form, as dengue hemorrhagic fever. While the vaccine is far from perfect, "it’s the best dengue vaccine so far," MIT immunologist Jianzhu Chen told The Verge. The new vaccine also reduced the number of people who needed to be hospitalized by bringing down the onset of fever by 80%. Fever is one of the virus's most potentially fatal complications, especially when it occurs in children under age 10. The vaccine is expected to be available in early 2015.
3. One-Drop Blood Testing

Bye, bye, needles.

Instead of getting blood drawn the conventional way, a new technology will let doctors — or pharmacists, even — run hundreds of tests with a single drop of blood from a finger prick. While a standard lipid panel, one of the most common blood tests done in the US, can cost between $10 and $100 depending on where it's done, the current advertised cost of the new test is $2.99.
4. Better Cholesterol-Reducing Drugs

Too much cholesterol in the blood can collect inside our arteries and plug them up, causing heart disease and death. While many people use statins, a special type of drug that can help lower cholesterol, some people's cholesterol levels simply don't respond to treatment.

There's a new type of injectable drug just for those patients called PCSK9. In studies, the drug has been successful at reducing cholesterol levels in people whose high cholesterol levels didn't respond to statins.

The best part? No trip to the hospital or clinic required. The drug can be injected at home, like insulin, and only requires one or two treatments a month. The FDA is expected to approve the first PCSK9 in 2015.

Cancer cellsjovan vitanovski/Shutterstock

5. Precision Cancer Treatment

Chemotherapy and radiation can save lives, but the intense treatment harms healthy cells in the process of taking down cancerous ones. As a result, many cancer patients experience side effects ranging from hair loss to crippling nausea and extreme fatigue.

But a new class of drugs targets cancer cells and leaves healthy tissues alone.

The drugs are a form of precision treatment that combines antibodies — the molecules the immune system uses to locate and stop harmful viruses — with a powerful toxin that kills a cancerous cell from within.

While these drugs, called antibody-drug conjugates, won't be a cure-all, more than 24 are in clinical trials for solid tumors and blood cancer. Some that have been designed to treat other types of cancer, including HER2-positive breast cancer and Hodgkin’s lymphoma, are already available.
6. Wireless Pacemaker

The first pacemaker was implanted in 1958. Since then, doctors have continued using pacemakers connected electrically to the heart via a complex system of tiny wires. Unfortunately, those wires can break or get dislodged in the body. Their insulation can also become cracked and lead to an infection.

This new pacemaker is wireless, 10% of the size of a conventional pacemaker (about the size of a large vitamin), and is implanted directly in the heart — no lengthy surgery required.

Doctors simply use a catheter in a leg vein to steer the device into the heart, a process that takes about 20 minutes. The lithium-battery-powered device lasts up to 7 years and is currently undergoing late stage clinical trials. It was first implanted into a patient in Ohio in February.

Pills
8. New Medications For Deadly Lung Disease

Idiopathic Pulmonary Fibrosis is a deadly, untreatable disease whose cause remains unknown. Scar tissue builds up inside the lungs, thickening its tissues and making breathing difficult. Many people diagnosed with IPF only live another 3-5 years; more than 30,000 Americans get such a diagnosis each year.

Two new drugs found to reduce scar tissue and improve lung function in patients got FDA approval in October. One appears to work by calming inflammation while the other blocks a protein that tells the lungs to make scar tissue. We don't yet know if these drugs will work for all patients, but they're the first that show promise in slowing the disease's progression.
9. Cheaper, More Convenient Breast Cancer Treatment

Close to a quarter million people will be diagnosed with breast cancer this year, according to the American Cancer Society; 40,000 women will die from the disease. Radiation therapy, the leading treatment used to beat back the disease, can be inconvenient and expensive. As a result, some people simply stop getting treatment, according to researchers at the Cleveland Clinic.

The Cleveland Clinic estimates that intraoperative radiation therapy, which would involve giving a patient a single dose of radiation after surgery to remove tumors, would cost one-fifth the sticker price of traditional radiation treatment, which can sometimes involve up to 20 doses.
10. A Pill That Protects The Heart From Failing

Nearly 55,000 people die each year when their hearts become too weak to pump blood. Today, most people at risk of heart failure treat their condition with two drugs: ACE inhibitors and beta blockers, which work by opening up the blood vessels and making it easier for the heart to push blood throughout the body. But they're not a perfect fix.

A new drug could further reduce the risk of heart failure. In a study of 8,000 patients, researchers testing the new treatment, called Angiotensin Receptor Neprilysin Inhibitor (ARNI), had to stop testing because the patients receiving the new drug had far better health outcomes than those taking traditional drugs. Compared to people taking traditional heart failure drugs, people getting ARNI were 20% less likely to be hospitalized for heart failure and 16% less likely to die from any cause during the study.

Read more: http://uk.businessinsider.com/how-will-medicine-change-in-2015-2014-11?r=US#ixzz3MBXjZYhr

 

 


Via ReactNow, Laurentiu Bogdan, dbtmobile
more...
Matt Coleman's curator insight, December 19, 3:24 AM

Let's hope some of these amazing new options make it to market in 2015

Rescooped by eMedToday from 9- PHARMA MULTI-CHANNEL MARKETING by PHARMAGEEK
Scoop.it!

Social Media Monitoring and Engagement in Pharma | InTouchMD

Social Media Monitoring and Engagement in Pharma | InTouchMD | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Social Media Monitoring and Engagement in the Pharma Industry

Via Lionel Reichardt / le Pharmageek
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

How Can Digital Health Startups Work With Health Insurers And Big Pharma? -

How Can Digital Health Startups Work With Health Insurers And Big Pharma? - | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Risk capital is fleeing or stagnant in most of health care. The exception is digital health.
more...
No comment yet.
Rescooped by eMedToday from Pharma & Medical Devices
Scoop.it!

Pharmaceutical Companies Look to Create Better Compassionate Use Process

The prominent US pharmaceutical trade group PhRMA has released an updated set of principles it says reflects the US pharmaceutical industry's "commitment" to provide patients with life-threatening diseases access to investigational therapies on a compassionate-use basis. 


Via Richard Meyer
more...
Richard Meyer's curator insight, December 12, 8:13 AM

The policy is meant to accommodate patients who are otherwise not eligible to participate in a clinical trial for a new drug, either because they are too sick to participate, have a disqualifying characteristic or are afflicted by an entirely different disease. -

Rescooped by eMedToday from Health, Digital Health, mHealth, Digital Pharma, hcsm latest trends and news (in English)
Scoop.it!

Social Media Monitoring for Pharma Engage with key influencers & opinion leaders

Social Media Monitoring for Pharma Engage with key influencers & opinion leaders | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Social Media Monitoring for Pharma Engage with key influencers & opinion leaders

Via Lionel Reichardt / le Pharmageek, Celine Sportisse
more...
No comment yet.
Rescooped by eMedToday from 4- PATIENT EMPOWERMENT & E-PATIENT by PHARMAGEEK
Scoop.it!

The key to successful clinical trial recruitment? Patient empowerment

The key to successful clinical trial recruitment? Patient empowerment | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Researchers at the University of Sussex have produced a white paper linking patient empowerment and a streamlined recruitment process with clinical recruitment success.

Via Lionel Reichardt / le Pharmageek
more...
No comment yet.
Scooped by eMedToday
Scoop.it!

Don't Get Caught With These Obsolete Digital Marketing Strategies

Don't Get Caught With These Obsolete Digital Marketing Strategies | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Being in the competitive world of digital marketing requires every internet marketer to exercise agility and flexibility in their marketing strategies.
more...
No comment yet.
Rescooped by eMedToday from Hospitals: Trends in Branding and Marketing
Scoop.it!

Despite eroding access to Physicians, opportunities for digital reach is increasing

Despite eroding access to Physicians, opportunities for digital reach is increasing | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
High-tech companies everywhere are scrambling to hire "data scientists"—but they struggle to find personnel who can crunch numbers and interpret the business implications.

Via Olivier Delannoy, COUCH. , eMedToday
more...
No comment yet.
Rescooped by eMedToday from Digital marketing pharma
Scoop.it!

Social media for pharma – an expert’s view

Social media for pharma – an expert’s view | Pharma: Trends and Uses Of Mobile Apps and Digital Marketing | Scoop.it
Even with risks and regulations, pharma needs to engage with patients and learn more about them

Via Olivier Delannoy
more...
No comment yet.